SVR 12 is expected at selleckchem the time of AASLD meeting. 56% of patients had hemoglobin less than 10 gm/dl- One patient received RBC transfusion, but completed 12 weeks

of treatment. 2 patients were hospitalized due to non-treatment related illnesses, but continued therapy uninterrupted. 4 patients required erythropoietin injection for anemia. There was no change in tacrolimus or sirolimus levels. On patients without baseline hyperbilrubinemia, the peak bilirubin during treatment was 2.9 mg/dl ( mean 1.8±0.5mg/ dl) . 10 patient had baseline mild to moderate renal insufficiency (calculated GFR or 40-60ml/min) and none of these patients experienced any further deterioration in renal function CONCLUSION. Simeprevir/sofosbuvir combination is safe in the setting of advanced HCV related graft dysfunction in liver transplant recipients. The on treatment virological response is 100% and preliminary SVR 4 results point to a potentially high SVR rates in these patients.

Disclosures: Satheesh Nair – Advisory Committees or Review Panels: Jansen; Speaking and Teaching: Gilead Sanjaya K. Satapathy – Advisory Committees or Review Panels: Gilead The following people have nothing Everolimus nmr to disclose: Nader Dbouk, Shilpa Lingala Purpose: The mechanism(s) by which ribavirin (RBV) exerts its clinical effects is largely unknown. Intracellular purine depletion may be a major mechanism of RBV’s antiviral activity and toxicity, but this has not been shown in vivo. We sought to determine the influence of RBV treatment on endogenous purine concentrations in patients

undergoing RBV-based antiviral therapy for Hepatitis C virus (HCV) infection. Methods: Red blood cells (RBC) were obtained from HCV genotype 1 infected patients undergoing HCV therapy with peginterferon alfa 2a and RBV with or without telaprevir. RBC samples were collected 2 hours after the first RBV dose (d1) and 4 weeks (wk4) and 8-14 weeks (steady state; wkSS) after beginning Oxaprozin HCV treatment. Adenosine triphosphate (ATP), guanosine tri-phosphate (GTP), and ribavirin triphosphate (RBV-TP) were measured using validated LC-MS/MS methods. Several statistical methods including Pearson rho correlation, t-tests, linear and logistic regression, and one-way ANOVA were utilized to examine associations between clinical covariates, antiviral (sustained virological response (SVR) vs. no SVR) and toxic (hemoglobin <10 vs. ≥10g/dL) effects and ATP and GTP levels. Results: ATP and GTP were quantified in 36 subjects [14 F/22 M, mean (SD) age 50 (8.6) years]. ATP levels were significantly reduced by RBV treatment (p=0.0006). Mean (SD) ATP at d1, wk4, wkSS were 127 (20.2), 82 (12.8), and 84 (17.0) pmol/million cells (M), respectively. Women had higher GTP levels at baseline compared to men, mean (SD) 5.5 (1.1) vs. 4.4 (0.96) pmol/M, p=0.003. RBV treatment reduced GTP levels in women at wk4 (by 16%, p=0.009), but not in men.